摘要
霍奇金淋巴瘤(hodgkin lymphoma,HL)是一种高度可治愈的恶性淋巴瘤,但仍有20%的HL患者会复发或进展为难治性HL。早期准确地预后评估是HL患者获得最佳治疗的重要前提。随着现代生物医学技术的发展,HL预后相关外周血生物标志物的研究不断取得进展,有望成为评估患者预后的可靠指标并指导临床治疗。全文对外周血生物标志物在HL预后方面的最新研究进展作一综述。
Hodgkin’s lymphoma(HL) is a highly curable malignant lymphoma,but about 20% HL patients will relapse or progress to refractory HL. Early and accurately evaluating the prognosis would help HL patients to get the best treatment. With the development of biomedical technology,the peripheral blood biomarkers are expected to become reliable indicators for evaluating the prognosis of HL patients and guiding clinical treatment. This review summarizes the recent advances in peripheral blood biomarkers for the prognosis of HL.
作者
单晓宇
马维维
张清媛
赵文辉
SHAN Xiao-yu;MA Wei-wei;ZHANG Qing-yuan;ZHAO Wen-hui(Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处
《肿瘤学杂志》
CAS
2021年第4期305-309,共5页
Journal of Chinese Oncology
